Magrietha Mallinson, Global Vertical Lead, Health at DP World discusses unlocking the potential of Africa's pharmaceutical market in our latest EPM Online insight.
Guillaume Wallart, CEO, CellQuest explores how diagnostics models can make autologous cell therapy manufacturing work in our latest EPM online insight.
In our first interview series of the year with Lonza, we spoke with Dr. Simon Wagschal, Associate Director, Advanced Chemistry Technologies, Lonza Small Molecules Global R&D and Dr. Aaron Johnson, Manager, Cheminformatics & Data Science, Lonza.
Dr. Danial Arkwell, Head of Global Key Accounts, Pharma at Envirotainer highlights the vital role of efficient logistics in getting orphan drugs to patients in desperate need.
BBI Solutions OEM Limited (BBI) has announced the successful closing of the acquisition of IBEX Technologies Inc. (IBEX), a leading developer and manufacturer of high-precision enzymes and diagnostic solutions located in Montréal, Québec.
The UK MHRA has approved the combined antibiotic cefepime/enmetazobactam (Exblifep 2 g/0.5 g powder for concentrate for solution for infusion) to treat adult patients with complicated infections of the urinary tract.
The EMPACT-MI phase III clinical trial showed a 10% relative risk reduction in the primary composite endpoint of time to first hospitalisation due to heart failure or all-cause mortality for empagliflozin versus placebo.
There is a real opportunity for AI to maximise Life Sciences companies’ investment in regulatory data management. ArisGlobal’s Agnes Cwienczek & Renato Rjavec set out practical examples of AI and Generative AI delivering tangible benefits.
With more gene therapy trials securing approval and getting underway globally, innovators are focusing on developing viral vector carrier technologies that are safer and more predictable.
Paul Knight, Managing Director of CME Automation Systems analyses one of the biggest challenges facing the life sciences industry: how to implement automated ‘just-in-time’ clinical supply chains.
Bespak have announced the completion of the transaction to separate Recipharm’s former Advanced Delivery Systems Business Unit from the Recipharm Group to form a new standalone company.
